Regenxbio Q1 FY26 net loss widens to $90.05 million; revenue drops 92.82% to $6.39 million

Regenxbio

Regenxbio

RGNX

0.00
  • Regenxbio posted a net loss of USD 90.05 million, swinging from net income of USD 6.08 million a year earlier, as revenue fell 92.83% to USD 6.39 million.
  • Operating loss widened to USD 83.36 million from operating income of USD 12.13 million, while research and development expense rose 8.01% to USD 57.34 million.
  • License and royalty revenue dropped 94.15% to USD 5.09 million, reflecting the absence of a USD 70 million upfront license revenue recognized in first-quarter 2025 and lower royalties.
  • Cost of license and royalty revenues climbed to USD 11.07 million from USD 3.44 million, driven by a non-recurring USD 10 million settlement charge tied to a GSK sublicense-fee dispute.
  • Cash, cash equivalents and marketable securities totaled USD 150.5 million at March 31, 2026; liquidity was expected to fund operations into early 2027, excluding potential milestone receipts such as a USD 100 million AbbVie payment tied to first dosing in the NAAVIGATE diabetic retinopathy trial expected in second-quarter 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-222804), on May 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.